Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Large Increase in Short Interest

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large increase in short interest in May. As of May 15th, there was short interest totaling 596 shares, an increase of 3,625.0% from the April 30th total of 16 shares. Based on an average daily volume of 6,288 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Ascentage Pharma Group International Price Performance

AAPG stock opened at $20.57 on Thursday. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The business has a 50 day moving average of $23.23 and a 200-day moving average of $25.90. Ascentage Pharma Group International has a 12-month low of $18.56 and a 12-month high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million during the quarter. On average, sell-side analysts predict that Ascentage Pharma Group International will post -1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on AAPG shares. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $46.67.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International during the third quarter worth about $96,000. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International in the third quarter valued at about $204,000. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at approximately $391,000. Finally, XY Capital Ltd increased its stake in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.